Immucell Corp (ICCC) 6.52 $ICCC
Bobbi Jo Brockmann Promoted to Vice President of Sales and Marketing
Marketwired - Thu Feb 12, 7:00AM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced that Bobbi Jo Brockmann (Kunde) has been promoted to Vice President of Sales and Marketing.
ICCC: 6.52 (-0.08)
ImmuCell's (ICCC) CEO Michael Brigham on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 11, 8:50PM CST
ICCC: 6.52 (-0.08)
ImmuCell EPS of $0.04
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 3:22PM CST
ICCC: 6.52 (-0.08)
ImmuCell Announces Financial Results for 2014
Marketwired - Wed Feb 11, 3:06PM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for 2014 and its fourth quarter ended December 31, 2014.
ICCC: 6.52 (-0.08)
ImmuCell to Announce 2014 Full Year and Fourth Quarter Financial Results
Marketwired - Wed Feb 04, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report 2014 full year and fourth quarter financial results after the market closes on Wednesday, February 11, 2015. The Company has scheduled a conference call that same day Wednesday, February 11, 2015, at 4:30 PM EST to review the results.
ICCC: 6.52 (-0.08)
ImmuCell to Present at LD Micro Conference on December 2, 2014
Marketwired - Tue Nov 25, 12:36PM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that Michael Brigham, President and Chief Executive Officer, will make a presentation at the LD Micro conference on Tuesday, December 2, 2014 at 5:30 PM PST / 8:30 PM EST.
ICCC: 6.52 (-0.08)
ImmuCell reports Q3 breakeven
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:17PM CST
ICCC: 6.52 (-0.08)
ImmuCell Announces Financial Results for Third Quarter of 2014
Marketwired - Wed Nov 12, 3:08PM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for its third quarter ended September 30, 2014.
ICCC: 6.52 (-0.08)
ImmuCell reports November 12
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:50PM CST
ICCC: 6.52 (-0.08)
ImmuCell to Announce Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Mon Nov 03, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report financial results for its third quarter fiscal year 2014 after the market closes on Wednesday, November 12, 2014. The Company has scheduled a conference call that same day Wednesday, November 12, 2014, at 4:30 pm EST to review the results.
ICCC: 6.52 (-0.08)
ImmuCell Participating at Multiple Dairy and Beef Industry Events Throughout September 2014
Marketwire - Wed Sep 17, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it will be participating in a number of large industry tradeshows throughout the month of September.
ICCC: 6.52 (-0.08)
ImmuCell Announces Financial Results for the Second Quarter of 2014
Marketwire - Tue Aug 12, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for its second quarter ended June 30, 2014.
ICCC: 6.52 (-0.08)
ImmuCell Initiates Pivotal Effectiveness Study to Prevent Calf Scours Caused by Rotavirus
Marketwire - Tue Jul 15, 7:02AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has commenced a pivotal effectiveness study designed to test antibodies derived from colostrum utilizing its proprietary technology against a bovine rotavirus challenge. The enrollment of calves for the pivotal effectiveness study is expected to be complete by the end of 2014, making product approval possible in 2015.
ICCC: 6.52 (-0.08)
ImmuCell Commences Manufacture of Nisin Necessary for Approval of Mast Out(R)
Marketwire - Wed Jul 09, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has completed modifications to its manufacturing facility to produce pharmaceutical-grade Nisin, the active ingredient in its Mast Out(R) product, to address subclinical mastitis in lactating dairy cows.
ICCC: 6.52 (-0.08)
Bobbi Jo Brockmann Promoted to Vice President of Sales and Marketing
Marketwired - Thu Feb 12, 7:00AM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced that Bobbi Jo Brockmann (Kunde) has been promoted to Vice President of Sales and Marketing.
ICCC: 6.52 (-0.08)
ImmuCell's (ICCC) CEO Michael Brigham on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 11, 8:50PM CST
ICCC: 6.52 (-0.08)
ImmuCell EPS of $0.04
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 3:22PM CST
ICCC: 6.52 (-0.08)
ImmuCell Announces Financial Results for 2014
Marketwired - Wed Feb 11, 3:06PM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for 2014 and its fourth quarter ended December 31, 2014.
ICCC: 6.52 (-0.08)
ImmuCell to Announce 2014 Full Year and Fourth Quarter Financial Results
Marketwired - Wed Feb 04, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report 2014 full year and fourth quarter financial results after the market closes on Wednesday, February 11, 2015. The Company has scheduled a conference call that same day Wednesday, February 11, 2015, at 4:30 PM EST to review the results.
ICCC: 6.52 (-0.08)
ImmuCell to Present at LD Micro Conference on December 2, 2014
Marketwired - Tue Nov 25, 12:36PM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that Michael Brigham, President and Chief Executive Officer, will make a presentation at the LD Micro conference on Tuesday, December 2, 2014 at 5:30 PM PST / 8:30 PM EST.
ICCC: 6.52 (-0.08)
ImmuCell reports Q3 breakeven
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:17PM CST
ICCC: 6.52 (-0.08)
ImmuCell Announces Financial Results for Third Quarter of 2014
Marketwired - Wed Nov 12, 3:08PM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for its third quarter ended September 30, 2014.
ICCC: 6.52 (-0.08)
ImmuCell reports November 12
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:50PM CST
ICCC: 6.52 (-0.08)
ImmuCell to Announce Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Mon Nov 03, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report financial results for its third quarter fiscal year 2014 after the market closes on Wednesday, November 12, 2014. The Company has scheduled a conference call that same day Wednesday, November 12, 2014, at 4:30 pm EST to review the results.
ICCC: 6.52 (-0.08)
ImmuCell Participating at Multiple Dairy and Beef Industry Events Throughout September 2014
Marketwire - Wed Sep 17, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it will be participating in a number of large industry tradeshows throughout the month of September.
ICCC: 6.52 (-0.08)
ImmuCell Announces Financial Results for the Second Quarter of 2014
Marketwire - Tue Aug 12, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for its second quarter ended June 30, 2014.
ICCC: 6.52 (-0.08)
ImmuCell Initiates Pivotal Effectiveness Study to Prevent Calf Scours Caused by Rotavirus
Marketwire - Tue Jul 15, 7:02AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has commenced a pivotal effectiveness study designed to test antibodies derived from colostrum utilizing its proprietary technology against a bovine rotavirus challenge. The enrollment of calves for the pivotal effectiveness study is expected to be complete by the end of 2014, making product approval possible in 2015.
ICCC: 6.52 (-0.08)
ImmuCell Commences Manufacture of Nisin Necessary for Approval of Mast Out(R)
Marketwire - Wed Jul 09, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has completed modifications to its manufacturing facility to produce pharmaceutical-grade Nisin, the active ingredient in its Mast Out(R) product, to address subclinical mastitis in lactating dairy cows.
ICCC: 6.52 (-0.08)
